{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036264","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.709044+00:00","generated_at":"2026-05-25T02:13:06.361368+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"enGene Q1 net loss $24.6M ($0.48/sh); cash $272.8M; LEGEND on track for BLA mid-2026","bullets":["Net loss $24.6M ($0.48 per share) for Q1 ended Jan 31, 2025, vs $10.7M ($0.46) a year ago.","Cash and marketable securities $272.8M; expected runway into 2027.","Total operating expenses $26.6M, up from $10.8M, driven by LEGEND study costs and headcount.","LEGEND pivotal cohort enrollment on track for BLA filing mid-2026; trial sites expanded to Europe/Asia.","Amended protocol adds maintenance dosing for patients in CR at 12 months up to 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036264","json":"https://secwatch.observer/filing/0000950170-25-036264.json","markdown":"https://secwatch.observer/filing/0000950170-25-036264.md","text":"https://secwatch.observer/filing/0000950170-25-036264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025036264/0000950170-25-036264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025036264/engn-20250310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T02:13:06.361368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}